VK2735: Dosing Protocols

Important Disclaimer#

VK2735 is an investigational drug not yet approved by any regulatory authority. All dosing information is derived from clinical trial protocols and published results. VK2735 should only be used within approved clinical trials. The information below is for educational purposes only.

Clinical Trial Dosing#

Subcutaneous Formulation (VENTURE Phase 2)#

The Phase 2 VENTURE trial evaluated weekly subcutaneous VK2735 at multiple dose levels with dose escalation over 13 weeks. Viking Therapeutics has not publicly disclosed all specific dose levels used in the trial.

Key observations from the dosing cohorts:

• Multiple escalating dose cohorts were evaluated
• The highest dose cohort achieved 14.7% mean weight loss
• 88% of patients in the highest dose group achieved 10% or more weight loss
• Weight loss was dose-dependent across cohorts
• No weight loss plateau was observed at 13 weeks

Oral Tablet Formulation (VENTURE-Oral Phase 2)#

The oral tablet formulation was evaluated in a separate Phase 2 trial with once-daily dosing:

• Multiple dose levels evaluated
• Highest dose achieved up to 12.2% weight loss at 13 weeks
• No strict fasting requirements reported (unlike oral semaglutide)

Phase 3 VANQUISH Program#

The Phase 3 VANQUISH program is evaluating VK2735 at doses selected based on the Phase 2 results:

• VANQUISH-1: Subcutaneous VK2735 in adults with obesity; over 4,500 patients enrolled
• VANQUISH-2: Additional Phase 3 trial

Specific Phase 3 dosing regimens have not been fully disclosed.

Dose Escalation#

Like other GLP-1 class therapies, VK2735 uses a dose escalation approach to improve GI tolerability. Patients start at a lower dose and gradually increase to the maintenance dose over several weeks. This gradual titration reduces the incidence and severity of nausea and other GI side effects.

Administration#

Subcutaneous Injection#

• Once-weekly injection
• Standard subcutaneous injection sites (abdomen, thigh, upper arm)
• Rotate injection sites between doses

Oral Tablet#

• Once-daily oral administration
• No strict fasting requirement reported
• Specific food interaction guidance has not been publicly disclosed

Comparison of Formulations#

Dosing Context#

VK2735 belongs to the Metabolic category of research peptides. Dosing protocols for VK2735 are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for VK2735:

undefined#

Dose: undefined

Frequency: Once weekly (subcutaneous)

Duration: 13 weeks in Phase 2; Phase 3 duration longer

Dose escalation was used to mitigate GI adverse events. The highest dose cohort showed the greatest weight loss with no plateau at 13 weeks.

undefined#

Dose: undefined

Frequency: Once daily (oral tablet)

Duration: 13 weeks in Phase 2

Oral formulation does not require the strict fasting conditions needed for oral semaglutide (Rybelsus), which is a potential convenience advantage.

Reconstitution and Preparation#

Not applicable - VK2735 is provided as a ready-to-use subcutaneous injection or oral tablet

Injection Sites#

Recommended injection sites for VK2735 include:

• Abdomen (subcutaneous formulation)
• Thigh (subcutaneous formulation)
• Upper arm (subcutaneous formulation)

Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.

Storage Requirements#

Storage conditions have not been publicly disclosed. Clinical trial formulations are managed per protocol requirements.

Related Reading#

• VK2735 overview and research guide
• VK2735 side effects profile
• VK2735 research evidence